Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00224133 is registered in ClinicalTrials.gov with Watson Pharmaceuticals as lead sponsor.

NCT NCT00224133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00224133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Open-Label Evaluation of the Safety of a New Drug in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
Watson Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
April 30, 2007
Enrollment
661 (actual)
Sites
79

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia